GLTO Galecto

Galecto to Participate in Leerink Partners 2026 Global Healthcare Conference

Galecto to Participate in Leerink Partners 2026 Global Healthcare Conference

BOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biotechnology company working to redefine care for people with hematologic disorders, today announced that company management will participate in a fireside chat at the Leerink Partners 2026 Global Healthcare Conference on Monday, March 9, 2026 at 10:40 a.m. ET.

A live webcast of the Company’s presentation will be available under the “News & Events” tab in the Investor Calendar section of the Company’s website at . An archived replay will be accessible for 30 days following the event.

About Galecto, Inc.

Galecto, Inc. is a clinical-stage biotechnology company advancing a pipeline of antibody therapeutics to transform treatment of a broad spectrum of hematological cancers. Galecto’s pipeline includes a highly differentiated mutant calreticulin (mut-CALR)-driven myeloproliferative neoplasm portfolio targeting essential thrombocythemia and myelofibrosis. Galecto’s pipeline also includes GB3226, a first-in-class preclinical dual inhibitor of ENL-YEATS and FLT3 for the treatment of multiple genetic subsets of acute myeloid leukemia.

Media Contact:

Lia Dangelico

Deerfield Group

Investor Contact:

Brian Ritchie

LifeSci Advisors



EN
02/03/2026

Underlying

GLTOGalecto

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Galecto

 PRESS RELEASE
Free
GLTO GALECTO

Galecto to Participate in Leerink Partners 2026 Global Healthcare Conf...

Galecto to Participate in Leerink Partners 2026 Global Healthcare Conference BOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biotechnology company working to redefine care for people with hematologic disorders, today announced that company management will participate in a fireside chat at the Leerink Partners 2026 Global Healthcare Conference on Monday, March 9, 2026 at 10:40 a.m. ET. A live webcast of the Company’s presentation will be available under the “News & Events” tab in the Investor Calendar section of the Company’s website at . An archived replay will...

March 2, 2026 1 EN
 PRESS RELEASE
Free
GLTO GALECTO

Galecto Announces Closing of Public Offering and Full Exercise of the ...

Galecto Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.3 Million BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers, today announced the closing of its previously announced underwritten public offering of 16,644,737 shares of its common stock, including the full exercise of the underwriters’ option to purchase up to 2,171,052 additional s...

February 12, 2026 1 EN
 PRESS RELEASE
Free
GLTO GALECTO

Galecto Announces Pricing of $275 Million Underwritten Public Offering

Galecto Announces Pricing of $275 Million Underwritten Public Offering BOSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers, today announced the pricing of its previously announced underwritten public offering of shares of its common stock. Galecto is selling a total of 14,473,685 shares of common stock at a public offering price of $19.00 per share. In addition, Galecto has granted the underwriters a 30-day option to purchase an a...

February 11, 2026 1 EN
 PRESS RELEASE
Free
GLTO GALECTO

Galecto Announces Proposed Underwritten Public Offering of Common Stoc...

Galecto Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock BOSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers, today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors that so choose, Series C non-voting convertible preferred stock. All of the securities are being offered by Galecto. In addition, Galecto i...

February 10, 2026 1 EN
 PRESS RELEASE
Free
GLTO GALECTO

Galecto Highlights Key Strategic Priorities and Anticipated 2026 Miles...

Galecto Highlights Key Strategic Priorities and Anticipated 2026 Milestones DMR-001, a potentially best-in-class mutant calreticulin (“mutCALR”) targeting monoclonal antibody, on track for expected IND submission, or equivalent, in mid-2026 with anticipated first-in-human dosing via subcutaneous administrationRecent addition of deep hematology/oncology drug development experience with the appointment of a Chief Operating Officer and Chief Medical OfficerPipeline of additional candidates advancing to the clinic, with first IND submission of DMR-002 expected in second half of 2026Cash balance...

January 12, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch